Skip to content
lifestyle.usfeatures.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
NervGen Pharma Corp.
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 13, 2026
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
March 4, 2026
NervGen Pharma to Participate at Upcoming Investor Conferences
February 18, 2026
←
Previous Page
1
2